Pharmaceuticals News and Research

RSS

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Particle Sciences has expanded its Bioanalytic Service's offerings to include Dried Blood Spot LC/MS/MS analysis (DBS). DBS is a growing area of interest because of its advantages in sample collection, stability, and simplified storage requirements. By using DBS, sample collection and processing is greatly simplified resulting in decreased costs, increased safety and greater comfort for test subjects.

4 Jun 2010

USP, Ukrainian Centre sign agreement to improve quality of pharmaceuticals worldwide

With the mutual goal of improving the quality of pharmaceuticals worldwide, the U.S. Pharmacopeial Convention and the Ukraine Scientific Pharmacopoeial Centre for the Quality of Medicines have entered into an agreement to share standards for the quality, purity, strength and identity of medicines.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in HER2 positive cancer patients will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8, 2010, in Chicago, Illinois.

4 Jun 2010

Research finding suggests possibilities for future treatment of anxiety disorders

Researchers at the University of Puerto Rico, School of Medicine have found a way to pharmacologically induce a memory of safety in the brain of rats. As reported in the June, 4 2010 issue of Science, administering brain-derived neurotrophic factor into the prefrontal cortex prevented rats from expressing fear to a tone that had been previously paired with a shock.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

BSGI effective for evaluating unclear mammographic or ultrasound findings

Researchers at the Legacy Good Samaritan Hospital in Portland, Oregon presented data on the clinical use of Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique, at the American Society of Breast Surgeons Annual meeting in Las Vegas in April: Breast Specific Gamma Imaging Used As An Adjunct to Mammography.

4 Jun 2010

CHOC Children's receives royalty-free research license to certain StemCells' patents

StemCells, Inc. and the Children's Hospital of Orange County ("CHOC Children's") announced today that they have entered into an agreement that provides CHOC Children's with a royalty-free research license to certain of StemCells' patents. This license authorizes CHOC Children's to proliferate, maintain and use human neural stem cells for non-commercial purposes.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

Millipore shareholders approve acquisition of all outstanding shares of common stock by Merck KGaA

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

European countries focus on drug price cuts

"European governments grappling to reduce large budget deficits are focusing their cost-cutting on a large spending item — pharmaceuticals," The Wall Street Journal reports. "Several countries in recent weeks, including Spain, Germany and Italy, have proposed or enacted reductions in what they will pay or taken other cost-control measures for various drugs.

4 Jun 2010

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS). The trial, referred to as ASMP3001, is the first of two Phase 3 trials being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for U.S. registration. This first trial will be conducted at 120 sites in the U.S.

4 Jun 2010

Pharmaceuticals News and Research

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

USP, Ukrainian Centre sign agreement to improve quality of pharmaceuticals worldwide

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Research finding suggests possibilities for future treatment of anxiety disorders

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

BSGI effective for evaluating unclear mammographic or ultrasound findings

CHOC Children's receives royalty-free research license to certain StemCells' patents

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

Millipore shareholders approve acquisition of all outstanding shares of common stock by Merck KGaA

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

European countries focus on drug price cuts

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Malvern publishes online chemical imaging bibliography

Taro's granisetron tablets receive FDA approval

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

First Edition: June 3, 2010

Pittcon Highlights: Pharmaceutical & Biologic eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News